Results 231 to 240 of about 1,213,487 (359)

The Value of Baseline [¹⁸F]FDG-PET in Predicting the Progression-Free Survival in Patients with Thymic Epithelial Tumours: A Systematic Review and Meta-Analysis. [PDF]

Diagnostics (Basel)
Miceli A, Librando M, Dondi F, Jonghi-Lavarini L, D'Antonio A, Mura A, Nappi AG, Rovera G, De Feo MS, Santo G, Lanfranchi F.   +10 more
europepmc   +1 more source

Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation: a retrospective study based on the time of HLA typing and donor availability

, 2010
Barbara Sarina, Luca Castagna, Lucia Farina, Francesca Patriarca, Fabio Benedetti, Angelo Michele Carella, Michele Falda, Stefano Guidi, Fabio Ciceri, Alessandro Bonini, Samantha Ferrari, Michele Malagola, Enrico Morello, Giuseppe Milone, Benedetto Bruno, Nicola Mordini, Simonetta Viviani, Alessandro Levis, Laura Giordano, Armando Santoro, Paolo Corradini   +20 more
openalex   +1 more source

Loss of aquaporin 3 protein expression constitutes an independent prognostic factor for progression-free survival: an immunohistochemical study on stage pT1 urothelial bladder cancer [PDF]

, 2012
Wolfgang Otto, Peter Rubenwolf, Maximilian Burger, Hans‐Martin Fritsche, Wolfgang Rößler, Matthias May, Arndt Hartmann, Ferdinand Hofstädter, Wolf F. Wieland, Stefan Denzinger   +9 more
openalex   +1 more source

The rapidly growing landscape of RAS inhibitors: from selective allele blockade to broad inhibition strategies

Molecular Oncology, EarlyView.
RAS‐targeted therapies have become a clinical reality. Although promising results in patients have been achieved, there are still challenges ahead such as coping with drug resistance. Here we summarize selected RAS inhibitors targeting either individual KRAS mutant isoforms (KRASG12C, KRASG12D, KRASG12V) or exhibiting a wider inhibitory spectrum ...
Matthias Drosten, Mariano Barbacid
wiley   +1 more source

Impact of concomitant use of pazopanib and gastric acid suppressants on progression-free survival and safety in patients with sarcoma: a retrospective study. [PDF]

J Pharm Health Care Sci
Isezaki T, Yuyama H, Yasumuro O, Miyaji Y, Funakoshi R.   +4 more
europepmc   +1 more source

Variations of the ataxia telangiectasia mutated gene in patients with chronic lymphocytic leukemia lack substantial impact on progression-free survival and overall survival: a Cancer and Leukemia Group B study [PDF]

, 2012
Gerard Lozanski, Amy S. Ruppert, Nyla A. Heerema, Arletta Lozanski, David Lucas, Amber Gordon, John G. Gribben, Vicki A. Morrison, M. Kanti, Guido Marcucci, Richard A. Larson, John C. Byrd   +11 more
openalex   +1 more source

A guide to reactive oxygen species in tumour hypoxia: measurement and therapeutic implications

Molecular Oncology, EarlyView.
Hypoxia reshapes tumour redox landscapes by altering compartmental ROS production (mitochondria, NOX, ER, peroxisomes). Accurate interpretation requires oxygen‐contextualised measurement (live biosensors, chemical probes, EPR, LC–MS) and awareness of artefacts (reoxygenation, probe specificity).
Lina Hacker, Elysia Sarsam, Stuart J. Conway, Ester M. Hammond   +3 more
wiley   +1 more source

Comparative study on the predictive value of TyG, TyG-BMI, and TG/HDL-C for progression-free survival in patients with locally advanced nasopharyngeal carcinoma. [PDF]

Front Nutr
Xiao Z, Liang Z, Chen W, Huang H, Qu S.
europepmc   +1 more source

Ro 31‐8220 suppresses bladder cancer progression via enhancing autophagy in vitro and in vivo

FEBS Open Bio, EarlyView.
The pan‐protein kinase C inhibitor Ro‐31‐8220 demonstrates potent anti‐bladder cancer effects both in vitro and in vivo by suppressing migration/invasion, inducing apoptosis and crucially activating autophagy, where blocking autophagy with chloroquine reduces its cell‐killing efficacy, suggesting its promise as a novel therapeutic candidate requiring ...
Shengjun Fu, Yan Tao, Shan Wu, Yuwen Gong, Youli Zhao, Shaomin Niu, Hui Cheng, You Mu, Na Xu, Ying Wang, Jianzhong Lu, Shanhui Liu, Lanlan Li   +12 more
wiley   +1 more source

Progression-Free Survival Under Immune Checkpoint Inhibitors for Metastatic Non-Small-Cell Lung Cancer: A Retrospective Cohort Study. [PDF]

Oncol Ther
Boré P, Geier M, Campion L, Raoul JL, Doucet L, Hiret S, Bigot F, Bocquet F, Mezquita L, Gorria T, Raimbourg J.   +10 more
europepmc   +1 more source